NCT03984747 (SPARO) is a clinical trial in Transplant Rejection, sponsored by Natera, Inc..

Who is sponsoring NCT03984747?

NCT03984747 is sponsored by Natera, Inc..

What condition does NCT03984747 study?

NCT03984747 studies Transplant Rejection, Allograft Rejection, Complications.

Is NCT03984747 still recruiting?

NCT03984747 is currently completed. Last updated 18 March 2025.

Last reviewed 2025-03-18 · How we verify

NCT03984747: SPARO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed Last updated 18 March 2025

What this trial tests

trial in Transplant Rejection in 110 participants. Completed in 23 August 2024.

Timeline

14 September 2018

Primary endpoint
23 August 2024

23 August 2024

Quick facts

Lead sponsor	Natera, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	110
Start date	14 September 2018
Primary completion	23 August 2024
Estimated completion	23 August 2024
Sites	4 locations across United States

Conditions studied

Transplant Rejection — all drugs for Transplant Rejection →
Allograft Rejection — all drugs for Allograft Rejection →
Complications — all drugs for Complications →

Sponsor

Natera, Inc.

Who can join

2 and older, any sex, with Transplant Rejection or Allograft Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection and Injury Status.
Thongprayoon C, Vaitla P, Craici IM, Leeaphorn N, et al · · 2020 · cited 38× · PMID 32423115 · DOI 10.3390/jcm9051480
Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review.
Chancharoenthana W, Traitanon O, Leelahavanichkul A, Tasanarong A. · · 2023 · cited 12× · PMID 37675106 · DOI 10.3389/fimmu.2023.1206929
Emerging role of cell-free DNA in kidney transplantation.
Chopra B, Sureshkumar KK. · · 2021 · cited 11× · PMID 34877265 · DOI 10.5493/wjem.v11.i5.55
The Current State of Donor-Derived Cell-Free DNA Use in Allograft Monitoring in Kidney Transplantation.
Kueht ML, Dongur LP, Cusick M, Stevenson HL, et al · · 2022 · cited 9× · PMID 36294839 · DOI 10.3390/jpm12101700
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation.
Raszeja-Wyszomirska J, Macech M, Kolanowska M, Krawczyk M, et al · · 2023 · cited 6× · PMID 37580899 · DOI 10.12659/aot.939750

Verify or expand the search:

Other recruiting trials for Transplant Rejection

Currently open trials in the same condition.

NCT06910527 — Study of the Plasma and Urinary cfDNA of in Kidney Transplant Patients · recruiting
NCT05156710 — BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) · Phase 2 · active not recruiting

Other Natera, Inc. trials

Trials by the same sponsor.

NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
NCT07046585 — Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) · recruiting
NCT06620627 — Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection · recruiting
NCT05309382 — Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation · completed
NCT05312814 — Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03984747 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Natera, Inc.
Last refreshed: 18 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03984747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing